Evaluating a new imaging technique for brain tumors
Application of 99mTc-CNDG SPECT/CT Imaging in the Diagnosis of Brain Tumors
This study is testing a new imaging method for brain tumors to see if it works better than the standard method currently used.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06362304 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to assess the effectiveness of 99mTc-CNDG SPECT/CT in diagnosing brain tumors by comparing its diagnostic consistency with the established 18F-FDG-PET method. Participants will undergo both imaging techniques within two weeks prior to surgery, allowing for a direct comparison against pathological diagnoses obtained from surgical or biopsy samples. The study seeks to determine the correlation between the maximum standardized uptake value (SUVmax) of 99mTc-CNDG and different tumor types.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a clinical diagnosis of brain tumors who can provide informed consent.
Not a fit: Patients with insulin-dependent diabetes, severe liver or kidney disease, or those undergoing current cancer treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the accuracy of brain tumor diagnoses, leading to better treatment planning.
How similar studies have performed: While there have been studies comparing various imaging techniques for brain tumors, the specific use of 99mTc-CNDG in this context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with clinical diagnosis of brain tumor; * Be at least 18 years old; * The final pathological results could be obtained by surgery or biopsy; * Informed consent and the ability to be followed up; * Those who did not meet the exclusion criteria. Exclusion Criteria: * Insulin-dependent diabetes mellitus or fasting blood glucose \>7 mmol/L before 99mTc-CNDG injection; * Severe liver or kidney disease (serum creatinine level \>3.0mg/dL or any liver enzyme level ≥ 5 times the upper limit of normal); * Severe hypersensitivity or hypersensitivity to radiocontrast agents; * Claustrophobia (inability to undergo SPECT/CT or PET/CT scans); * Patients receiving radiotherapy and chemotherapy; * Being pregnant or breastfeeding.
Where this trial is running
Beijing, Beijing Municipality
- Peking Union Medical College Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Zhaohui Zhu
- Email: 13611093752@163.com
- Phone: 01069154241
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.